DexCom PT Raised to $48.00 (DXCM)
Research analysts at Canaccord Genuity boosted their price target on shares of DexCom (NASDAQ:DXCM) from $40.00 to $48.00 in a report released on Thursday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 25.62% from the stock’s previous close.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. DexCom presently has an average rating of “Hold” and an average price target of $40.40.
In other DexCom news, SVP Andrew K. Balo unloaded 10,000 shares of the company’s stock on the open market in a transaction dated Friday, July 25th. The shares were sold at an average price of $38.19, for a total transaction of $381,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of DexCom (NASDAQ:DXCM) traded up 13.40% on Thursday, hitting $43.33. 526,149 shares of the company’s stock traded hands. DexCom has a one year low of $21.85 and a one year high of $49.83. The stock has a 50-day moving average of $38.52 and a 200-day moving average of $38.4. The company’s market cap is $3.246 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.